Results 141 to 150 of about 26,349 (219)

Present and Future Options for Pharmacotherapy in Cardiovascular Disease: Hemodynamic and Mechanistic Therapeutic Targets. [PDF]

Med Sci (Basel)
Cabré F, Cascante M.
europepmc   +1 more source

Best practices in specialized hypertrophic cardiomyopathy centers in the United States: a survey of cardiologists, nurses, pharmacists, patients, and patient advocates. [PDF]

Future Cardiol
Maron M, Steeves B, Wang A.
europepmc   +1 more source

Targeting the Sarcomere: Myosin Inhibitors as the Revolutionary Game Changer in Hypertrophic Cardiomyopathy. [PDF]

Rev Cardiovasc Med
Sedaghat-Hamedani F, Kayvanpour E, Meder B.   +2 more
europepmc   +1 more source

Understanding immune checkpoint inhibitors-related myocarditis: Mechanisms and targeted therapeutic pathways. [PDF]

Theranostics
Xia W, Zhang H, Liu L, Tu C, Song X.
europepmc   +1 more source

Transient epigenetic changes promote cardiomyocyte differentiation of the subcutaneous adipose stromal vascular fraction. [PDF]

Regen Ther
Shinjo Y, Takashima S, Goten C, Inoue O, Hashimuko D, Yamaguchi K, Takeda Y, Sakata K, Takamura M, Usui S.   +9 more
europepmc   +1 more source

Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy. [PDF]

J Cardiovasc Dev Dis
Ferraresi B, Nenna A, Jawabra M, Corrado D, Faggiano A, Carugo S, Dominici C, Casali G, Chello M, Lusini M.   +9 more
europepmc   +1 more source

Therapeutic Response to Myosin Inhibitor Therapy in Noonan Syndrome-Associated Obstructive Hypertrophic Cardiomyopathy. [PDF]

JACC Case Rep
Feidakis A, Nies R, Kural M, Pennig L, Winnerling N, Erger F, Pfister R, Seuthe K.   +7 more
europepmc   +1 more source

Cardiogenic shock and atrial fibrillation after mavacamten dose escalation in obstructive hypertrophic cardiomyopathy: a case report. [PDF]

Eur Heart J Case Rep
Jeong WJ, Kim SE, Cho SW, Namgung J, Ko KY.   +4 more
europepmc   +1 more source

Single-cell transcriptomic insights into the immune heterogeneity of immune checkpoint inhibitors related organ toxicities. [PDF]

Front Immunol
Wen H, Qi Y, Song J, Yan X.
europepmc   +1 more source

Mavacamten inhibits myosin activity by stabilizing the myosin interacting-heads motif and stalling motor force generation. [PDF]

Sci Adv
McMillan SN, Pitts JRT, Barua B, Winkelmann DA, Scarff CA.   +4 more
europepmc   +1 more source